文献速递湿疹皮炎与荨麻疹

阿布昔替尼治疗难治性特应性皮炎的真实世界疗效

Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-08-02

这项前瞻性观察性单中心研究纳入41例中度至重度特应性皮炎患者,评估阿布昔替尼在标准诊疗中的疗效与安全性。中位随访25周,EASI中位数从基线14.7降至末次评估4.0,瘙痒NRS中位数从7.0降至3.0(均p<0.001)。

要点

  • 中位随访25周,EASI中位数由14.7降至4.0,瘙痒NRS由7.0降至3.0,均p<0.001。
  • 73.2%患者曾对其他靶向治疗无效,包括JAK抑制剂34%和生物制剂39%。
  • 最常见不良事件为胃肠道症状27.6%、痤疮20.7%和呼吸道感染17.2%。

核心结论

  • 阿布昔替尼在日常实践中对中度至重度特应性皮炎有效,包括对其他靶向治疗无应答者。

主要发现

  • 中位随访25周(IQR 16-34),EASI中位数从基线14.7(IQR 10.4-25.4)降至末次评估4.0(IQR 1.6-11.4),p<0.001。
  • 瘙痒NRS中位数从基线7.0(IQR 5-8)降至末次评估3.0(IQR 1-2),p<0.001。
  • 30例(73.2%)曾对其他靶向治疗无效,其中JAK抑制剂14例(34%)、生物制剂16例(39%)。
  • 最常见不良事件为胃肠道症状27.6%、痤疮20.7%、呼吸道感染17.2%。
  • 16例(39%)因无效、不良事件或两者停药,分别占41.2%、41.2%和11.8%。

临床怎么用

  • 阿布昔替尼可用于中度至重度特应性皮炎的日常治疗,包括对其他靶向治疗无应答的患者。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abrocitinib is a JAK-1 selective inhibitor registered for the treatment of moderate-to-severe atopic dermatitis (AD). Although efficacy and safety have been shown in phase 3 clinical trials, data on real-world patients with a treatment history of advanced systemics are scarce. OBJECTIVES: The objective of the study was to evaluate the effectiveness and safety of abrocitinib treatment in patients with difficult-to-treat AD in daily practice. METHODS: In this prospective observational single-centre study, all AD patients who started abrocitinib treatment in the context of standard care between April 2021 and December 2022 were included. Effectiveness was assessed using clinician- and patient-reported outcome measures. Adverse events were evaluated. RESULTS: Forty-one patients were included. The majority (n = 30; 73.2%) had failed (ineffectiveness) on other targeted therapies, including JAK inhibitors (n = 14, 34%) and biologics (n = 16, 39%). Abrocitinib treatment resulted in a significant decrease in disease severity during a median follow-up period of 25 weeks (IQR 16-34). Median EASI score at baseline decreased from 14.7 (IQR 10.4-25.4) to 4.0 (IQR 1.6-11.4) at last review (p < 0.001). Median NRS itch decreased from 7.0 (IQR 5-8) to 3.0 (IQR 1-2) at last review (p < 0.001). The most frequently reported AEs included gastrointestinal symptoms (27.6%), acne (20.7%) and respiratory tract infections (17.2%). 16 (39%) patients discontinued abrocitinib treatment due to ineffectiveness, AEs or both (41.2%, 41.2% and 11.8%, respectively). CONCLUSION: Abrocitinib can be an effective treatment for patients with moderate-to-severe AD in daily practice, including non-responders to other targeted therapies.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Olydam JI, Schlösser AR, Custurone P, et al. Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis. J Eur Acad Dermatol Venereol. 2023. PMID: 37478296. doi:10.1111/jdv.19378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。